The weight-loss drug market is experiencing a boom, yet the spoils are not being shared equally.

Eli Lilly saw its shares surge more than 8% in premarket trading on Wednesday.

This followed the company's report of quarterly sales and profits that surpassed expectations, driven by soaring revenue from its weight-loss drugs Zepbound and Mounjaro.

Eli Lilly also projected that its full-year 2026 sales would grow approximately 25% compared to the previous year, a forecast that also exceeded analyst estimates.

In stark contrast, Novo-Nordisk A/S shares fell 18% during European trading after the firm warned on Tuesday that its 2026 sales growth would be slower than anticipated due to pricing pressures in the U.S. for its drugs Wegovy and Ozempic.

Although Novo-Nordisk A/S was a pioneer in the obesity drug market, Eli Lilly has surpassed it in several key areas, including drug efficacy, manufacturing capacity, and direct-to-consumer sales strategies.

This year, the performance of both companies' oral weight-loss pills will be a major focus. Novo-Nordisk A/S launched its pill earlier this year, while Eli Lilly is still awaiting approval from the U.S. Food and Drug Administration (FDA).